Aggressive B-Cell Lymphoma
Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Loretta Nastoupil, MDVideo Insights | September 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
View More
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | September 14, 2023
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
Cecilia BrownAggressive B-Cell Lymphoma | August 25, 2023
A first-in-human phase I trial will evaluate escalating doses of BITT2101 in patients with non-Hodgkin lymphoma.
Cecilia BrownAggressive B-Cell Lymphoma | August 1, 2023
The application for the approval of epcoritamab is based on results from the phase I/II EPCORE NHL-1 trial.
Cecilia BrownPrint | July 19, 2023
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
Cecilia BrownAggressive B-Cell Lymphoma | July 18, 2023
The phase II study previously showed pembrolizumab had effective antitumor activity and acceptable safety in R/R PMBCL.
Leah SherwoodAggressive B-Cell Lymphoma | July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Kerri FitzgeraldAggressive B-Cell Lymphoma | June 16, 2023
The FDA approves the first bispecific antibody for relapsed/refractory DLBCL.
Keightley AmenMeeting News | June 8, 2023
A new global, multicenter study is enrolling patients with newly diagnosed diffuse large B-cell lymphoma.
Jason Westin, MDAggressive B-Cell Lymphoma | June 6, 2023
The study compared axicabtagene ciloleucel with standard‑of‑care therapy in patients with relapsed or refractory LBCL.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | June 6, 2023
Dr. Nastoupil discusses findings from TRANSFORM subgroup analyses.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | June 5, 2023
CAR T-cell therapy with lisocabtagene maraleucel resulted in survival benefits for patients with relapsed or refractory.
Cecilia BrownMeeting News | June 5, 2023
Dr. Dickinson and colleagues presented the research at the 2023 American Society of Clinical Oncology Annual Meeting.
Keightley AmenAggressive B-Cell Lymphoma | June 4, 2023
Targeted induction immunochemotherapy with ibrutinib or lenalidomide and R-MPV is feasible, according to the researchers.
Cecilia BrownMeeting News | June 1, 2023
ZUMA-23 will be the first phase III randomized controlled study to evaluate CAR-T as a frontline regimen for any cancer.
Cecilia BrownAggressive B-Cell Lymphoma | May 19, 2023
The accelerated approval follows the FDA granting priority review to the Biologics License Application.
Blood Cancer TalksBlood Cancer Talks | May 19, 2023
This episode provides listeners with DLBCL management strategies and an overview of the latest research in the field.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 18, 2023
Drs. Vijenthira and Prica discuss their study and why its results differed from a similar study published in late 2022.
Leah SherwoodAggressive B-Cell Lymphoma | May 16, 2023
The approval is based on results from the pivotal phase III TRANSFORM trial.
Cecilia BrownAggressive B-Cell Lymphoma | April 19, 2023
The FDA approval of pola-R-CHP for first-line treatment of DLBCL is based on pivotal data from the phase III POLARIX trial.
Editorial Board